October 31, 2020

Regeneron Announces Presentation of Additional REGN-COV2 COVID-19 Outpatient Trial Results at the 20th Annual Meeting of the Federation of Clinical Immunology Societies

Regeneron President and Chief Scientific Officer George Yancopoulos, MD, Ph.D. presented today during a session at the 20th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 20). During the presentation, Dr. Yancopoulos shared additional detail on the recently announced positive prospective results from the COVID-19 outpatient trial. Slides from today's presentation can be found here.

Forward-Looking Statements and Use of Digital Media

This statement and the presentation discussed herein include forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products and product candidates and research and clinical programs now underway or planned, including without limitation the development program relating to REGN-COV2 (Regeneron's investigational dual antibody for the treatment and prevention of COVID-19); safety issues resulting from the administration of Regeneron's product candidates (such as REGN-COV2) in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; whether the U.S. Food and Drug Administration will grant an Emergency Use Authorization ("EUA") for REGN-COV2 and, if an EUA is granted, the scope and terms of such EUA and how long such EUA would remain in effect for REGN-COV2; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's product candidates (such as REGN-COV2); the ability of Regeneron to manufacture in anticipated quantities Regeneron's product candidates, including REGN-COV2; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's product candidates, including without limitation REGN-COV2; and the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and

Exchange Commission, including its Form 10-K for the year ended December 31, 2019 and its Form 10-Q for the quarterly period ended June 30, 2020. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

Contacts:

Media Relations
media@regeneron.com

Investor Relations
investor@regeneron.com